Sri Krishna Pharmaceuticals Limited - Unit IV – FDA 483, Aug 4, 2023
An FDA inspection of Sri Krishna Pharmaceutical LTD, an API manufacturer in Telangana, India, revealed significant deficiencies across its quality system. The firm was cited for inadequate investigations into out-of-specification results and data integrity issues, as well as failures in laboratory controls and equipment design. Further observations included insufficient cleaning validation and a deficient stability monitoring program, indicating a systemic lack of robust quality oversight and control over critical manufacturing and testing processes.
ID · 566b8d68-3168-49cd-bb9e-4e61526c5d23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.